These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 23998921)

  • 1. Thienopyrimidine bisphosphonate (ThPBP) inhibitors of the human farnesyl pyrophosphate synthase: optimization and characterization of the mode of inhibition.
    Leung CY; Park J; De Schutter JW; Sebag M; Berghuis AM; Tsantrizos YS
    J Med Chem; 2013 Oct; 56(20):7939-50. PubMed ID: 23998921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of potent bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase via targeted interactions with the active site 'capping' phenyls.
    De Schutter JW; Shaw J; Lin YS; Tsantrizos YS
    Bioorg Med Chem; 2012 Sep; 20(18):5583-91. PubMed ID: 22884353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.
    Lin YS; Park J; De Schutter JW; Huang XF; Berghuis AM; Sebag M; Tsantrizos YS
    J Med Chem; 2012 Apr; 55(7):3201-15. PubMed ID: 22390415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase.
    Park J; Leung CY; Matralis AN; Lacbay CM; Tsakos M; Fernandez De Troconiz G; Berghuis AM; Tsantrizos YS
    J Med Chem; 2017 Mar; 60(5):2119-2134. PubMed ID: 28208018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.
    De Schutter JW; Park J; Leung CY; Gormley P; Lin YS; Hu Z; Berghuis AM; Poirier J; Tsantrizos YS
    J Med Chem; 2014 Jul; 57(13):5764-76. PubMed ID: 24911527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzyme's active site closure.
    Park J; Lin YS; De Schutter JW; Tsantrizos YS; Berghuis AM
    BMC Struct Biol; 2012 Dec; 12():32. PubMed ID: 23234314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanistic insights into protonation state as a critical factor in hFPPS enzyme inhibition.
    Fernández D; Ortega-Castro J; Mariño L; Perelló J; Frau J
    J Comput Aided Mol Des; 2015 Jul; 29(7):667-80. PubMed ID: 26081258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure of human farnesyl pyrophosphate synthase in complex with an aminopyridine bisphosphonate and two molecules of inorganic phosphate.
    Park J; Lin YS; Tsantrizos YS; Berghuis AM
    Acta Crystallogr F Struct Biol Commun; 2014 Mar; 70(Pt 3):299-304. PubMed ID: 24598914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of thienopyrimidine-based inhibitors of the human farnesyl pyrophosphate synthase--parallel synthesis of analogs via a trimethylsilyl ylidene intermediate.
    Leung CY; Langille AM; Mancuso J; Tsantrizos YS
    Bioorg Med Chem; 2013 Apr; 21(8):2229-2240. PubMed ID: 23477945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crystallographic and thermodynamic characterization of phenylaminopyridine bisphosphonates binding to human farnesyl pyrophosphate synthase.
    Park J; Rodionov D; De Schutter JW; Lin YS; Tsantrizos YS; Berghuis AM
    PLoS One; 2017; 12(10):e0186447. PubMed ID: 29036218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyl pyrophosphate synthase inhibitors with antiosteoporosis efficacy in ovariectomized rats: A mixed binding approach beyond bisphosphonates.
    El-Sayed NF; El-Hussieny M; Mansour ST; Fouad MA; Saad MA; Ewies EF
    Eur J Med Chem; 2024 Oct; 276():116679. PubMed ID: 39018923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase.
    Gritzalis D; Park J; Chiu W; Cho H; Lin YS; De Schutter JW; Lacbay CM; Zielinski M; Berghuis AM; Tsantrizos YS
    Bioorg Med Chem Lett; 2015 Mar; 25(5):1117-23. PubMed ID: 25630225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.
    Wiemer AJ; Tong H; Swanson KM; Hohl RJ
    Biochem Biophys Res Commun; 2007 Feb; 353(4):921-5. PubMed ID: 17208200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel bisphosphonates with antiresorptive effect in bone mineralization and osteoclastogenesis.
    Savino S; Toscano A; Purgatorio R; Profilo E; Laghezza A; Tortorella P; Angelelli M; Cellamare S; Scala R; Tricarico D; Marobbio CMT; Perna F; Vitale P; Agamennone M; Dimiccoli V; Tolomeo A; Scilimati A
    Eur J Med Chem; 2018 Oct; 158():184-200. PubMed ID: 30216851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
    Kavanagh KL; Guo K; Dunford JE; Wu X; Knapp S; Ebetino FH; Rogers MJ; Russell RG; Oppermann U
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7829-34. PubMed ID: 16684881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase.
    De Schutter JW; Zaretsky S; Welbourn S; Pause A; Tsantrizos YS
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5781-6. PubMed ID: 20801032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
    Dunford JE
    Curr Pharm Des; 2010; 16(27):2961-9. PubMed ID: 20722615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
    Dunford JE; Kwaasi AA; Rogers MJ; Barnett BL; Ebetino FH; Russell RG; Oppermann U; Kavanagh KL
    J Med Chem; 2008 Apr; 51(7):2187-95. PubMed ID: 18327899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.